CTA has experienced significant growth over recent years, which has accelerated throughout 2019. Dedicating time to team development activities not only helps to integrate new staff into the wider [...]
I am pleased to share with you the 2018 Cancer Trials Australia Annual Report. Download the 2018 Annual Report Here. The 2018 calendar year saw growth in both CTA [...]
Invest Victoria recently profiled the strength of interactions between Cancer Trials Australia and BeiGene, a rapidly growing Chinese biopharmaceutical company, with over 1,700 staff across four continents and more than [...]
CTA has executed an MOU with ShareRoot Limited (ASX: SRO) to explore the application of ShareRoot’s MediaConsent platform as a tool to improve the dynamics of clinical trial recruitment, patient [...]
CTA announces partnership in delivering coordinated Electronic Document Management for Victorian study sites Cancer Trials Australia (CTA) is pleased to announce a new project funded by the Victorian Comprehensive [...]
Due to an improved partnership between South West Healthcare (SWH) and CTA, cancer patients will have greater access to potentially life-saving therapies they may not have otherwise had access to. SWH medical oncologist Ian [...]
Cancer Trials Australia is pleased to announce the addition of our 26th major healthcare provider member, Calvary Central Districts Hospital, located in South Australia. This partnership builds on Calvary's [...]
Cancer Trials Australia (CTA) is pleased to announce execution of a Services Agreement with the VCCC to provide Site Management Services for the VCCC’s Investigator Initiated Trial Program. Professor [...]
I am pleased to share the 2017 Cancer Trials Australia Annual Report. Download the 2017 Annual Report Here. 2017 saw expansion of CTA membership and significant growth in CTA services for [...]
Cancer Trials Australia celebrates their support of 1,000 commercially sponsored clinical trials and the recruitment of 8,000 patients, in conjunction with International Clinical Trials Day on May 21st, 2018 Since [...]
Cancer Trials Australia's CEO, Dr Kurt Lackovic, was recently invited to speak at an international webinar showcasing Melbourne as a premier location for the conduct of Phase 1 clinical trials. Aimed primarily at international [...]
More patients will have access to potentially life-saving cancer therapies as a result of Epworth joining forces with Cancer Trials Australia. With the addition of Epworth, CTA now has [...]
I am pleased to share the Cancer Trials Australia 2016 Annual Report. Download the 2016 Annual Report Here. 2016 saw growth in CTA membership and corresponding CTA service activity. CTA welcomed [...]
Cancer Trials Australia (CTA) is pleased to announce that Linear Clinical Research has signed a Members Agreement to join the CTA Member Network The CTA network now includes 24 [...]
Cancer Trials Australia (CTA) is proud to be part of the successful Cancer Council Victoria (CCV) grant application for the establishment of a cancer clinical trials network across seven [...]
Chairman of the Board, Professor Andrew Scott, with great pleasure advised that the next Chief Executive Officer of Cancer Trials Australia (CTA) will be Dr Kurt Lackovic. Professor Scott said [...]
Cancer Trials Australia (CTA) announced today that the Shepparton Hospital, through Goulburn Valley Health, and Northern Adelaide Cancer Centre Clinical Trials Unit, operating as the Lyell McEwin Hospital, have [...]
A new RAF-targeted therapeutic has shown early promise against tumours in Phase 1 trials. Doctors Jayesh Desai (1), Ben Solomon (2) and Hui Gan (3)have established a highly successful collaboration [...]
Cancer Trials Australia (CTA) announced today that South West Healthcare had signed an agreement to join CTA. "Southwest Healthcare located at Warrnambool in Victoria services a large population over South [...]
The Board of Directors of Cancer Trials Australia (CTA) today announced the appointment of Professor Andrew Scott as Chairperson.This appointment was made by the Board following the resignation of Professor [...]
